Antimicrobial Efficiency of Mutacin 1140 Extract on Oral Streptococci
Article Sidebar
Published:
Feb 16, 2018
Main Article Content
Abstract
The present study aimed to determine the efficiency of mutacin 1140 extract in inhibiting and killing mutans and non-mutans streptococci. Mutacin 1140 was prepared from the culture medium of Streptococcus mutans JH1140 by extraction and purification with chloroform. Protein concentration of mutacin 1140 extract was determined by colorimetric detection with the bicinchoninic acid assay. Minimum inhibitory and bactericidal concentrations of mutacin 1140 extract against six bacterial species (i.e., S. mutans, S. sobrinus, S. mitis, S. gordonii, S. sanguinis and S. salivarius) were determined by using broth microdilution assay. The time-kill assay for each bacteria was performed at the bactericidal concentration of mutacin 1140 extract for S. mutans. The results showed that mutacin 1140 extract had greater inhibitory and bactericidal activities against non-mutans streptococci than mutans streptococci. In addition, S. sobrinus were more sensitive than S.mutans to the antimicrobial activity of mutacin 1140 extract. The times required for complete eradication of more sensitive and less sensitive bacteria were 30 and 60 minutes, respectively. In conclusion, all other oral streptococci tested in this study are more susceptible than S. mutans to the inhibitory and bactericidal activities of mutacin 1140 extract. Hence, this study warrants further research into drug delivery systems targeting mutans streptococci for dental caries control.
Article Details
How to Cite
1.
Palakawong na Ayudhya C, Luengpailin S, Lulitanond V. Antimicrobial Efficiency of Mutacin 1140 Extract on Oral Streptococci. Khon Kaen Dent J [Internet]. 2018 Feb. 16 [cited 2024 Apr. 25];20(2):1-10. Available from: https://he01.tci-thaijo.org/index.php/KDJ/article/view/112168
Issue
Section
Research Articles
บทความ ข้อมูล เนื้อหา รูปภาพ ฯลฯ ที่ได้รับการลงตีพิมพ์ในวิทยาสารทันตแพทยศาสตร์ มหาวิทยาลัยขอนแก่นถือเป็นลิขสิทธิ์เฉพาะของคณะทันตแพทยศาสตร์ มหาวิทยาลัยขอนแก่น หากบุคคลหรือหน่วยงานใดต้องการนำทั้งหมดหรือส่วนหนึ่งส่วนใดไปเผยแพร่ต่อหรือเพื่อกระทำการใด ๆ จะต้องได้รับอนุญาตเป็นลายลักษณ์อักษร จากคณะทันตแพทยศาสตร์ มหาวิทยาลัยขอนแก่นก่อนเท่านั้น
References
1. Palmer RJ Jr, Gordon SM, Cisar JO, Kolenbrander PE.Coaggregation-mediated interactions of streptococci and actinomyces detected in initial human dental plaque. J Bacteriol 2003;185(11):3400-09.
2. Socransky SS, Haffajee AD. Periodontal microbial ecology. Periodontol 2000 2005;38135-187.
3. Smith DJ, King WF, Taubman MA. Salivary IgA antibody to oral streptococcal antigens in predentate infants. Oral Microbiol Immunol 1990;5(2):57-62.
4. Smith DJ, Anderson JM, King WF, van Houte J, Taubman MA. Oral streptococcal colonization of infants. Oral Microbiol Immunol 1993;8(1):1-4.
5. Rosan B, Lamont RJ. Dental plaque formation. Microbes Infect 2000;2(13):1599-607.
6. Hamada S, Slade HD. Biology, immunology, and cariogenicity of Streptococcus mutans. Microbiol Rev 1980;44(2):331-84.
7. Loesche WJ. Role of Streptococcus mutans in human dental decay. Microbiol Rev 1986;50(4):353-80.
8. Gibbons RJ, Cohen L, Hay DI. Strains of Streptococcus mutans and Streptococcus sobrinus attach to different pellicle receptors. Infect Immun 1986;52(2):555-61.
9. Koga T, Asakawa H, Okahashi N, Hamada S. Sucrosedependent cell adherence and cariogenicity of serotype c Streptococcus mutans. J Gen Microbiol 1986;132(10):2873-83.
10. Kreth J, Zhu L, Merritt J, Shi W, Qi F. Role of sucrose in the fitness of Streptococcus mutans. Oral Microbiol Immunol 2008;23(3):213-19.
11. Hojo K, Nagaoka S, Ohshima T, Maeda N. Bacterial interactions in dental biofilm development. J Dent Res 2009;88(11):982-90.
12. Hamada S, Ooshima T. Inhibitory spectrum of a bacteriocinlike substance (mutacin) produced by some strains of Streptococcus mutans. J Dent Res 1975;54(1):140-45.
13. Hillman JD, Johnson KP, Yaphe BI. Isolation of a Streptococcus mutans strain producing a novel bacteriocin. Infect Immun 1984;44(1):141-44.
14. Hillman JD, Novak J, Sagura E, Gutierrez JA, Brooks TA, Crowley PJ et al. Genetic and biochemical analysis of mutacin 1140, a lantibiotic from Streptococcus mutans. Infect Immun 1998;66(6):2743-49.
15. Neeti D, Noel C, Dayna E, Shi-En L, Leif S. Optimization of the Production of the Lantibiotic Mutacin 1140 in Minimal Media. Process Biochem 2010;45(7):1187-91.
16. Espinel-Ingroff A, Fothergill A, Ghannoum M, Manavathu E, Ostrosky-Zeichner L, Pfaller M et al. Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole. J Clin
Microbiol 2005;43(10):5243-46.
17. Ghobrial OG, Derendorf H, Hillman JD. Pharmacodynamic activity of the lantibiotic MU1140. Int J Antimicrob Agents 2009;33(1):70-74.
18. Chan C, Burrows LL, Deber CM. Helix induction in antimicrobial peptides by alginate in biofilms. J Biol Chem 2004;279(37):38749-54.
19. Chen S, Wilson-Stanford S, Cromwell W, Hillman JD, Guerrero A, Allen CA, et al. Site-directed mutations in the lanthipeptide mutacin 1140. Appl Environ Microbiol 2013;79(13):4015-23.
20. Daly KM, Cotter PD, Hill C, Ross RP. Lantibiotic production by pathogenic microorganisms. Curr Protein Pept Sci 2012;13(6):509-23.
21. Mei L, Ren Y, Busscher HJ, Chen Y, van der Mei HC. Poisson analysis of streptococcal bond-strengthening on saliva-coated enamel. J Dent Res 2009;88(9):841-45.
22. Harper DS, Loesche WJ. Growth and acid tolerance of human dental plaque bacteria. Arch Oral Biol 1984;29(10):843-48.
23. Kreth J, Merritt J, Shi W, Qi F. Competition and coexistence between Streptococcus mutans and Streptococcus sanguinis in the dental biofilm. J Bacteriol 2005;187(21):7193-203.
24. Kreth J, Zhang Y, Herzberg MC. Streptococcal antagonism in oral biofilms: Streptococcus sanguinis and Streptococcus gordonii interference with Streptococcus mutans. J Bacteriol 2008;190(13):4632-640.
25. Caufield PW, Dasanayake AP, Li Y, Pan Y, Hsu J, Hardin JM. Natural history of Streptococcus sanguinis in the oral cavity of infants: evidence for a discrete window of infectivity. Infect Immun 2000;68(7):4018-023.
26. Quivey RG, Jr., Faustoferri R, Monahan K, Marquis R. Shifts in membrane fatty acid profiles associated with acid adaptation of Streptococcus mutans. FEMS Microbiol Lett 2000;189(1):89-92.
27. Fozo EM, Quivey RG, Jr. Shifts in the membrane fatty acid profile of Streptococcus mutans enhance survival in acidic environments. Appl Environ Microbiol 2004;70(2):929-36.
28. Smith L, Zachariah C, Thirumoorthy R, Rocca J, Novak J, Hillman JD, et al. Structure and dynamics of the lantibiotic mutacin 1140. Biochemistry 2003;42(35):10372-84.
29. Smith L, Hasper H, Breukink E, Novak J, Cerkasov J, Hillman JD, et al. Elucidation of the antimicrobial mechanism of mutacin 1140. Biochemistry 2008;47(10):3308-14.
30. de Kruijff B, van Dam V, Breukink E. Lipid II: a central component in bacterial cell wall synthesis and a target for antibiotics. Prostaglandins Leukot Essent Fatty Acids 2008;79(3-5):117-21.
31. Escano J, Deng P, Lu SE, Smith L. Draft Genome Sequence of Oral Bacterium Streptococcus mutans JH1140. Genome Announc 2016;4(3).
32. Bali V, Panesar PS, Bera MB, Kennedy JF. Bacteriocins: Recent Trends and Potential Applications. Crit Rev Food Sci Nutr 2016;56(5):817-34.
33. Yang SC, Lin CH, Sung CT, Fang JY. Antibacterial activities of bacteriocins: application in foods and pharmaceuticals. Front Microbiol 2014;5:241.
34. Rogers LA, Whittier EO. Limiting Factors in the Lactic Fermentation. J Bacteriol 1928;16(4):211-29.
35. Gharsallaoui A, Oulahal N, Joly C, Degraeve P. Nisin as a Food Preservative: Part 1: Physicochemical Properties, Antimicrobial Activity, and Main Uses. Crit Rev Food Sci Nutr 2016;56(8):1262-74.
36. Fox JL. Antimicrobial peptides stage a comeback. Nat Biotechnol 2013;31(5):379-82.
37. Dischinger J, Basi Chipalu S, Bierbaum G. Lantibiotics: promising candidates for future applications in health care. Int J Med Microbiol 2014;304(1):51-62.
38. Chugunov A, Pyrkova D, Nolde D, Polyansky A, Pentkovsky V, Efremov R. Lipid-II forms potential “landing terrain” for lantibiotics in simulated bacterial membrane. Sci Rep 2013;3:1678.
39. Ghobrial O, Derendorf H, Hillman JD. Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140. J Pharm Sci 2010;99(5):2521-28.
40. Ghobrial O, Derendorf H, Hillman JD. Human serum binding and its effect on the pharmacodynamics of the lantibiotic MU1140. Eur J Pharm Sci 2010;41(5):658-64.
41. Hillman JD, Brooks TA, Michalek SM, Harmon CC, Snoep JL, van Der Weijden CC. Construction and characterization of an effector strain of Streptococcus mutans for replacement therapy of dental caries. Infect Immun 2000;68(2):543-49.
42. Hillman JD, Mo J, McDonell E, Cvitkovitch D, Hillman CH. Modification of an effector strain for replacement therapy of dental caries to enable clinical safety trials. J Appl Microbiol 2007;102(5):1209-19.
43. Sandiford SK. Perspectives on lantibiotic discovery - where have we failed and what improvements are required? Expert Opin Drug Discov 2015;10(4):315-20.
2. Socransky SS, Haffajee AD. Periodontal microbial ecology. Periodontol 2000 2005;38135-187.
3. Smith DJ, King WF, Taubman MA. Salivary IgA antibody to oral streptococcal antigens in predentate infants. Oral Microbiol Immunol 1990;5(2):57-62.
4. Smith DJ, Anderson JM, King WF, van Houte J, Taubman MA. Oral streptococcal colonization of infants. Oral Microbiol Immunol 1993;8(1):1-4.
5. Rosan B, Lamont RJ. Dental plaque formation. Microbes Infect 2000;2(13):1599-607.
6. Hamada S, Slade HD. Biology, immunology, and cariogenicity of Streptococcus mutans. Microbiol Rev 1980;44(2):331-84.
7. Loesche WJ. Role of Streptococcus mutans in human dental decay. Microbiol Rev 1986;50(4):353-80.
8. Gibbons RJ, Cohen L, Hay DI. Strains of Streptococcus mutans and Streptococcus sobrinus attach to different pellicle receptors. Infect Immun 1986;52(2):555-61.
9. Koga T, Asakawa H, Okahashi N, Hamada S. Sucrosedependent cell adherence and cariogenicity of serotype c Streptococcus mutans. J Gen Microbiol 1986;132(10):2873-83.
10. Kreth J, Zhu L, Merritt J, Shi W, Qi F. Role of sucrose in the fitness of Streptococcus mutans. Oral Microbiol Immunol 2008;23(3):213-19.
11. Hojo K, Nagaoka S, Ohshima T, Maeda N. Bacterial interactions in dental biofilm development. J Dent Res 2009;88(11):982-90.
12. Hamada S, Ooshima T. Inhibitory spectrum of a bacteriocinlike substance (mutacin) produced by some strains of Streptococcus mutans. J Dent Res 1975;54(1):140-45.
13. Hillman JD, Johnson KP, Yaphe BI. Isolation of a Streptococcus mutans strain producing a novel bacteriocin. Infect Immun 1984;44(1):141-44.
14. Hillman JD, Novak J, Sagura E, Gutierrez JA, Brooks TA, Crowley PJ et al. Genetic and biochemical analysis of mutacin 1140, a lantibiotic from Streptococcus mutans. Infect Immun 1998;66(6):2743-49.
15. Neeti D, Noel C, Dayna E, Shi-En L, Leif S. Optimization of the Production of the Lantibiotic Mutacin 1140 in Minimal Media. Process Biochem 2010;45(7):1187-91.
16. Espinel-Ingroff A, Fothergill A, Ghannoum M, Manavathu E, Ostrosky-Zeichner L, Pfaller M et al. Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole. J Clin
Microbiol 2005;43(10):5243-46.
17. Ghobrial OG, Derendorf H, Hillman JD. Pharmacodynamic activity of the lantibiotic MU1140. Int J Antimicrob Agents 2009;33(1):70-74.
18. Chan C, Burrows LL, Deber CM. Helix induction in antimicrobial peptides by alginate in biofilms. J Biol Chem 2004;279(37):38749-54.
19. Chen S, Wilson-Stanford S, Cromwell W, Hillman JD, Guerrero A, Allen CA, et al. Site-directed mutations in the lanthipeptide mutacin 1140. Appl Environ Microbiol 2013;79(13):4015-23.
20. Daly KM, Cotter PD, Hill C, Ross RP. Lantibiotic production by pathogenic microorganisms. Curr Protein Pept Sci 2012;13(6):509-23.
21. Mei L, Ren Y, Busscher HJ, Chen Y, van der Mei HC. Poisson analysis of streptococcal bond-strengthening on saliva-coated enamel. J Dent Res 2009;88(9):841-45.
22. Harper DS, Loesche WJ. Growth and acid tolerance of human dental plaque bacteria. Arch Oral Biol 1984;29(10):843-48.
23. Kreth J, Merritt J, Shi W, Qi F. Competition and coexistence between Streptococcus mutans and Streptococcus sanguinis in the dental biofilm. J Bacteriol 2005;187(21):7193-203.
24. Kreth J, Zhang Y, Herzberg MC. Streptococcal antagonism in oral biofilms: Streptococcus sanguinis and Streptococcus gordonii interference with Streptococcus mutans. J Bacteriol 2008;190(13):4632-640.
25. Caufield PW, Dasanayake AP, Li Y, Pan Y, Hsu J, Hardin JM. Natural history of Streptococcus sanguinis in the oral cavity of infants: evidence for a discrete window of infectivity. Infect Immun 2000;68(7):4018-023.
26. Quivey RG, Jr., Faustoferri R, Monahan K, Marquis R. Shifts in membrane fatty acid profiles associated with acid adaptation of Streptococcus mutans. FEMS Microbiol Lett 2000;189(1):89-92.
27. Fozo EM, Quivey RG, Jr. Shifts in the membrane fatty acid profile of Streptococcus mutans enhance survival in acidic environments. Appl Environ Microbiol 2004;70(2):929-36.
28. Smith L, Zachariah C, Thirumoorthy R, Rocca J, Novak J, Hillman JD, et al. Structure and dynamics of the lantibiotic mutacin 1140. Biochemistry 2003;42(35):10372-84.
29. Smith L, Hasper H, Breukink E, Novak J, Cerkasov J, Hillman JD, et al. Elucidation of the antimicrobial mechanism of mutacin 1140. Biochemistry 2008;47(10):3308-14.
30. de Kruijff B, van Dam V, Breukink E. Lipid II: a central component in bacterial cell wall synthesis and a target for antibiotics. Prostaglandins Leukot Essent Fatty Acids 2008;79(3-5):117-21.
31. Escano J, Deng P, Lu SE, Smith L. Draft Genome Sequence of Oral Bacterium Streptococcus mutans JH1140. Genome Announc 2016;4(3).
32. Bali V, Panesar PS, Bera MB, Kennedy JF. Bacteriocins: Recent Trends and Potential Applications. Crit Rev Food Sci Nutr 2016;56(5):817-34.
33. Yang SC, Lin CH, Sung CT, Fang JY. Antibacterial activities of bacteriocins: application in foods and pharmaceuticals. Front Microbiol 2014;5:241.
34. Rogers LA, Whittier EO. Limiting Factors in the Lactic Fermentation. J Bacteriol 1928;16(4):211-29.
35. Gharsallaoui A, Oulahal N, Joly C, Degraeve P. Nisin as a Food Preservative: Part 1: Physicochemical Properties, Antimicrobial Activity, and Main Uses. Crit Rev Food Sci Nutr 2016;56(8):1262-74.
36. Fox JL. Antimicrobial peptides stage a comeback. Nat Biotechnol 2013;31(5):379-82.
37. Dischinger J, Basi Chipalu S, Bierbaum G. Lantibiotics: promising candidates for future applications in health care. Int J Med Microbiol 2014;304(1):51-62.
38. Chugunov A, Pyrkova D, Nolde D, Polyansky A, Pentkovsky V, Efremov R. Lipid-II forms potential “landing terrain” for lantibiotics in simulated bacterial membrane. Sci Rep 2013;3:1678.
39. Ghobrial O, Derendorf H, Hillman JD. Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140. J Pharm Sci 2010;99(5):2521-28.
40. Ghobrial O, Derendorf H, Hillman JD. Human serum binding and its effect on the pharmacodynamics of the lantibiotic MU1140. Eur J Pharm Sci 2010;41(5):658-64.
41. Hillman JD, Brooks TA, Michalek SM, Harmon CC, Snoep JL, van Der Weijden CC. Construction and characterization of an effector strain of Streptococcus mutans for replacement therapy of dental caries. Infect Immun 2000;68(2):543-49.
42. Hillman JD, Mo J, McDonell E, Cvitkovitch D, Hillman CH. Modification of an effector strain for replacement therapy of dental caries to enable clinical safety trials. J Appl Microbiol 2007;102(5):1209-19.
43. Sandiford SK. Perspectives on lantibiotic discovery - where have we failed and what improvements are required? Expert Opin Drug Discov 2015;10(4):315-20.